NVIDIA launches Jetson Thor robotics computers for physical AI systems
Investing.com -- Fulcrum Therapeutics (NASDAQ:FULC) stock rose 20% after the company announced plans to present topline results from the 12 mg dose cohort of its Phase 1b PIONEER trial of pociredir in sickle cell disease.
The clinical-stage biopharmaceutical company will host a conference call and webcast on Tuesday, July 29, 2025, at 8:00 a.m. ET to discuss the findings. Fulcrum management will be joined by Dr. Sheinei Alan, Director of the Inova Fairfax Adult Sickle Cell Program, and Dr. Wally Smith, Director at the VCU Adult Sickle Cell Program.
Fulcrum Therapeutics focuses on developing small molecules to improve the lives of patients with genetically defined rare diseases. The upcoming presentation of the PIONEER trial results represents a significant milestone in the company’s development of pociredir as a potential treatment for sickle cell disease.
Investors responded positively to the announcement, driving the stock up substantially in anticipation of the data presentation. The significant share price movement reflects market interest in the company’s progress with its sickle cell disease treatment candidate.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.